

ABOUT UNICANCER

Unicancer represents a federation of French Comprehensive Cancer Centres (FCCCs), 18 private, non-profit hospitals located throughout France. FCCCs are dedicated to fighting cancer through a threefold mission of patient care, research and education.

>>> For more information, please visit our website: www.unicancer.fr/en

FRENCH COMPREHENSIVE CANCER CENTRES (FCCCs)*

More than
20 000

employees and approximately 145,000 patients hospitalized each year – mainly with solid tumours or advanced cancers

Approximately
600

active clinical trials

15.2%

of the patients treated in the FCCCs are included in a clinical trial, vs 8.5% of cancer patients in France as a whole

PLATFORMS AND RESEARCH UNITS OF EXCELLENCE*

19

Molecular Biology Platforms French NCI (INCa) accredited among FCCCs

6

FCCCs are French NCI accredited **integrated cancerology research sites (SIRIC)** out of 8 in France

12

FCCCs are INCa-accredited **early-phase clinical trial centres (CLIP²)**, out of 16 in France

UNICANCER SPONSORED RESEARCH

55

active clinical trials

Including 15 new trials launched in 2018

206

investigator sites involved, including foreign institutions

More than
6300

patients included

* 2018 figures



R&D
101, rue de Tolbiac
75013 Paris
France

Claire LABREVEUX
Director of the Unicancer's R&D
c-labreveux@unicancer.fr

Anne-Laure MARTIN
Development, Partnerships
and Strategic Alliances Director
al-martin@unicancer.fr

Jean-Alexandre BOULENT
Development officer
ja-boulent@unicancer.fr

About our charity Partners

We are in close long-term partnerships on shared axes of research with the French Cancer League and the ARC Foundation, two non-profit organisations that subsidise cancer research.



www.unicancer.fr/en

Juillet 2019



Unicancer's R&D: Optimising collaborations to foster innovation

THE LEADING FRENCH ACADEMIC CLINICAL RESEARCH ORGANISATION IN ONCOLOGY

UNICANCER'S R&D: YOUR ACADEMIC PARTNER OF CHOICE FOR ONCOLOGY RESEARCH

Our ambition > develop mutually beneficial partnerships with public and private stakeholders involved in oncology research both in France and internationally
> create new networks structured around innovation

Our technical extensive network of experts and scientific collaborations, our research portfolio, our technical platform, as our integrated structure and our independence conferred by the non-profit private status put the Unicancer's R&D in the best position to address your research challenges.

ACADEMIC EXCELLENCE IN CANCER RESEARCH, FOR THE BENEFIT OF PATIENTS

Unicancer is one of the largest cancer care and research organisations in Europe. Created in 1994, Unicancer's Research & Development Department is a mutualised clinical and translational research entity.

This integrated structure can rely on 18 French Comprehensive Cancer Centres (FCCCs) non-profit private healthcare institutions spread across 20 hospitals in France. **Unicancer's R&D works with most of the public and private hospitals involved in cancer treatment in France, as well as with more than 100 hospitals across Europe and the main international cooperative groups involved in cancer research.** The Unicancer's R&D is accredited by the Ministry of Health and is eligible for public grants.



Unicancer's R&D is ISO 9001 certified:

- effective structure of the clinical research carried out in our 18 FCCCs and of our Unicancer R&D department
- high quality of our clinical research capacity for patients, doctors and academical and industrial partners
- strength of our many research branches all working under the same common values of our network: humanity, the pursuit of excellence, solidarity and innovation.

OUR RESEARCH PRIORITIES

FACILITATE PATIENT ACCESS TO INNOVATION FOR A BETTER CARE

> Develop innovative research into targeted therapies and immunotherapy programs

PROMOTE CLINICAL RESEARCH IN AREAS NEGLECTED BY THE PHARMACEUTICAL INDUSTRY

> Rare cancers, paediatric & elderly populations, surgery, radiotherapy, supportive care

ENCOURAGE TRANSLATIONAL RESEARCH AND INCREASE CANCER KNOWLEDGE TO DEVELOP THE THERAPEUTIC WEAPONS OF TOMORROW

> Biological samples are collected in every clinical trial, with access for research

OPTIMISE THERAPEUTIC STRATEGIES

> Design studies to adapt treatments and therapeutic sequences according to prognostic criteria

BETTER UNDERSTAND THE MECHANISMS OF TREATMENT RESPONSE, TOXICITIES AND RESISTANCE

> Generate large prospective or retrospective epidemiological cohorts

WHAT THE UNICANCER'S R&D CAN BRING TO YOUR ORGANISATION

FCCCs

A unique national network of 18 FCCCs, which are private non-profit hospitals dedicated to fighting cancer through a threefold mission: care, research and education.

Technical platforms

Access to state-of-the-art technical platforms within the FCCCs, fully equipped for molecular screening, translational research, bioinformatics, etc.

Expert Groups

Internationally recognised scientific and medical expertise provided by cooperative groups of top level clinicians and scientists, all oriented towards research, excellence and innovation for the benefit of the patients.

ESME

Our Epidemiology Strategy and Medical Economic department devoted to the collection and analysis of Real World Data.

unicancer
R&D

Clinical operations

An in-house clinical operations department of highly skilled, dedicated teams, allowing customised partnerships: Unicancer's R&D can act as a full sponsor or a preferred partner in collaborative researches.

A unique network

A powerful network of scientific collaborations with other cancer research groups at a national and international level, as well as with stakeholders from the public and private sectors.

Unicancer's R&D hosts the French liaison office of the European Organisation for Research and Treatment of Cancer (EORTC).

Biobank & Data centre

A centralised biobank and an FDA compliant centralised data centre.



MATWIN

A unit for maturation & accelerating translation with Industry.

UNICANCER EXPERT GROUPS

To fulfil its objectives, Unicancer's R&D works closely with internationally recognised groups of experts and provides the necessary support structure for efficient project management.

UNICANCER TUMOUR GROUPS

All Unicancer tumour groups share common goals:

- > evaluate existing and new therapeutic strategies
- > improve patient prognosis and quality of life through personalised treatments
- > develop innovative approaches to cancer treatment
- > identify predictors of treatment response, resistance and toxicity.

To achieve these goals, the Unicancer tumour groups develop strategic clinical research programs with a strong translational component relying on a systematic centralised banking of biological samples.

These research programs involve the FCCCs' units and platforms as well as a large number of public and private hospitals in France.

All the Unicancer tumour groups are moving towards international trials thanks to various partnerships with other cooperative groups and strong collaborations with industry.

French Breast Cancer Intergroup (UCBG)*

President: Thomas BACHELOT, Centre Léon Bérard, Lyon

COLLABORATIONS

French / EU level: French NCI / GENMED / European academic groups (UK NCRN, SAKK, GBG) / SOGUG / European intergroups (BIG, EORTC)

International level: SWOG, MCCRC

Strategic priorities: subtypes with poor prognosis / biology-driven strategies of therapeutic de-escalation / long-term follow-up data

Genitourinary Group (GETUG)*

President: Karim FIZAZI, Gustave Roussy, Villejuif

COLLABORATIONS

French / EU level: AFU / CeRePP / GERICO / AFSOS / EORTC / PEACE (Prostate Consortium in Europe) / EBMT

International level: various key opinion leaders in the genitourinary field

Strategic priorities: biobanking / proof of concept studies / therapeutic strategies evaluation / real-life data / medico economics

Gastrointestinal Group (UCGI)*

President: Emmanuelle SAMALIN, Institut de cancérologie de Montpellier (ICM)

COLLABORATIONS

French / EU level: FFCD & GERCOR within the PRODIGE intergroup / EORTC

International level: NCI of Canada / Canadian Cancer Trials Group

Strategic priorities: translational research / innovative studies / improvement of therapeutic strategies in adjuvant and metastatic setting

Sarcoma Group (UC Sarcoma)*

President: Jean-Yves BLAY, Centre Léon Bérard, Lyon

COLLABORATIONS

French / EU level: INCa / GSF-GETO French Sarcoma Group / Go-AJA / INTERSARC / EORTC / EuroEwing consortium / Patient Advocacy Groups

Strategic priorities: improvement of initial management of sarcomas and rare connective tissue tumours / biobanking / translational research

Head & Neck Group (UCH&N)*

President: Joël GUIGAY, Centre Antoine Lacassagne, Nice

COLLABORATIONS

French / EU level: GORTEC, GETTEC, GERCOR within the head & neck intergroup / EORTC

Strategic priorities: early-phase studies / rare cancers / biology driven medicine

LEXIQUE

AFSOS	French Association of Supportive care in cancer
AFU	French Association of Urology
BIG	Breast International Group
CeRePP	Research group on prostate cancer and urologic tumors
EBMT	European Society for Blood and Marrow Transplantation
EORTC	European Organisation for Research and Treatment of Cancer
FFCD	French group of Digestive Oncology
GBG	German Breast Group
GENMED	Laboratory of Excellence in MEDical GENomics
GERCOR	Multidisciplinary Cooperative Group in Oncology
GETTEC	French Head & Neck cancer Study Group
GORTEC	Cooperative Group of Radiation therapy for head and neck cancer
Go-AJA	Adolescents and Young Adults onco-haematology Group
INCa	French National Cancer Institute
INTERSARC	French network of Cooperative Groups in the field of sarcoma
MCCRC	Mayo Clinic Cancer Research Consortium
SAKK	Swiss Group for Clinical Cancer Research
SWOG	SouthWest Oncology Group
UK NCRN	UK National Cancer Research Network

* INCa accredited-group

The Unicancer expert groups are multidisciplinary groups dedicated to developing and steering innovative clinical studies. Their goals are to optimise treatment strategies and to contribute to scientific education and dissemination in their field, through participation in conferences and publications.

Six of the Unicancer Expert Groups are accredited by the French National Cancer Institute (INCa), thus acknowledging their excellence in research and operating capabilities.

UNICANCER CROSS-PATHOLOGY GROUPS

Personalised Medicine Program

President: Fabrice ANDRE, Gustave Roussy, Villejuif

The Unicancer Personalised Medicine Program develops multidrug predictors to allow selection of the most effective treatments for individual patients. This multidisciplinary group of experts in biology driven medicine develops programs which aim towards: proof of concept for personalized treatments, identification of predictors of sensitivity or resistance to therapy, identification of biomarkers of relapse or extreme responses, and validation of therapeutic decision algorithms based on biological tests. Cross-pathology trials are developed in close collaboration with several tumour-specific groups in France.

Immuno-Oncology Group

President: Frédérique Penault-Llorca, Centre Jean Perrin, Clermont-Ferrand

Created in 2016, the Unicancer Immuno-Oncology Group embodies Unicancer's strong desire to be a major player in cancer immunotherapy research. Bringing together renowned researchers and clinicians from the fields of immunology and oncology, this group offers a framework for cross-fertilization and a dozen clinical and translational studies involving immune checkpoint inhibitors are already underway

Oncogeriatrics Group (GERICO)*

President: Loïc MOUREY, Institut Claudius Régaud, Toulouse

The Unicancer Oncogeriatrics Group forms, together with the UCOG oncogeriatric coordination units, the DIALOG intergroup, which is accredited by the French NCI. It brings together oncologists, geriatricians, radiotherapists, surgeons, biostatisticians and pharmacologists, all

working towards promoting clinical research and innovation in oncogeriatrics and tailoring clinical trials for the elderly population by adapting the methodological approach and rationalising diagnostic and treatments.

Translational Research and Development in Radiation Oncology (UNITRAD)

President: Sofia RIVERA, Gustave Roussy, Villejuif

The Unicancer Translational Research and Development in Radiation Oncology Group's goal is to promote innovative and strategic radiotherapy research programs, and to develop collaborative networks. Its experts work on numerous topics such as brachytherapy, imaging, modelling and radiomics, radiobiology and radio-potential, ionising radiation, quality assurance, and methodology.

Supportive Care Intergroup

President: Ivan KRAKOWSKI, Institut Bergonié, Bordeaux and Florence JOLY, Centre François Baclesse, Caen

The Unicancer-AFSOS Supportive Care Intergroup has set itself the ambitious goal to design and conduct high-standards clinical programs using the most up-to-date and optimal methodology available, including the evaluation of quality of life and, whenever possible, a cost-efficiency analysis. Building a bridge with humanities and social sciences has also become key to this group.

SHAPING THE RESEARCH OF TOMORROW

CANTO

This clinico-biological cohort including 12 000 women with early breast cancer aims to quantify and predict treatment related chronic toxicities, and to evaluate psychological, social and economic impact of these toxicities in patients.

SAFIR

These "umbrella" studies assess the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer or metastatic non-small cell lung cancer.

AcSé

These "basket" studies, led by Unicancer under the auspices of the French NCI (INCa), provide secure access to innovative therapies for patients (including children) with tumours harbouring the corresponding molecular signature. Four projects, have been launched by Unicancer : two with targeted therapies, and two allowing treatment of patients presenting rare cancers with anti-PD-1 immunotherapies.

ESME

Launched in 2014, ESME is the first French independent academic "real life" database in oncology, centralising all longitudinal data available in routine practice. Its aim is to describe the use of cancer treatments and assess available therapeutic strategies. There are three ongoing programs: metastatic breast cancer, ovarian cancer and advanced & metastatic lung cancer.

EXPRESS

This cohort study aims to identify genetic characteristics unique to patients presenting an unexpected and exceptional response to targeted therapies.

MyPeBS

MyPeBS (My Personal Breast Screening) is a unique international EU-funded clinical study sponsored by Unicancer that compares a personalised risk-based screening strategy to standard screening among 85,000 women aged 40 to 70 in Belgium, France, Israel, Italy, and the United Kingdom.